Description: Cadonilimab is a bispecific immune checkpoint inhibitor that targets both PD-1 and CTLA-4, two pathways that cancer cells can use to suppress the body's immune response. By blocking these signals, it helps enhance the immune system's ability to recognize and attack tumor cells. Cadonilimab is approved for the treatment of persistent, recurrent, or metastatic cervical cancer, including certain patients whose disease has progressed after platinum-based chemotherapy, and may be used in combination with chemotherapy in specific treatment settings. It is also indicated for locally advanced unresectable or metastatic gastric and gastroesophageal junction (G/GEJ) adenocarcinoma when used as part of combination therapy, making it an important option in the evolving field of cancer immunotherapy.
Category: Health & Fitness
Tag: Cadonilimab in India, Cadonilimab Injection in India, PD-1 Inhibitor, CTLA-4 Inhibitor, Bispecific Antibody, Cancer Immunotherapy, Cervical Cancer Treatment, Gastric Cancer Treatment, Gastroesophageal Junction Adenocarcinoma, Advanced Cancer Therapy, Onco